Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• BRAF mutations occur in 4% of non-small cell lung cancer (NSCLC) cases.
• BRAF mutations are classified into three subtypes: class I (V600E), and class II and III (non-V600), with varying clinical implications.
• Targeted therapies are crucial for managing this patient subset.

Purpose of the Study:

• To provide a concise and updated review of therapeutic strategies for NSCLC patients with BRAF mutations.
• To highlight the different treatment approaches for V600E versus non-V600 BRAF mutations.
• To discuss emerging therapeutic avenues for BRAF-mutant NSCLC.

Main Methods:

• Review of pivotal phase II trials and current research on BRAF-mutant NSCLC.
• Analysis of therapeutic efficacy for different BRAF mutation subtypes.
• Exploration of novel combination therapies and their potential impact.

Main Results:

• Double BRAF/MEK inhibition (dabrafenib plus trametinib) is effective for V600E-mutated NSCLC.
• Non-V600 BRAF mutations constitute approximately 50% of BRAF-mutant NSCLC, lacking approved targeted therapies.
• Investigational strategies include combinations with immune-checkpoint inhibitors and selective ERK 1/2 inhibitors.

Conclusions:

• BRAF mutation status is a critical factor in NSCLC treatment selection.
• Current approved therapies primarily target the V600E subtype.
• Further research into novel combinations is essential to address the unmet needs of patients with non-V600 BRAF mutations in NSCLC.